Krystal Biotech Stock
Krystal Biotech Stock
We can see a decrease in the price for Krystal Biotech. Compared to yesterday it has lost -€3.400 (-1.560%).
With 23 Buy predictions and not a single Sell prediction Krystal Biotech is an absolute favorite of our community.
However, we have a potential of -3.2% for Krystal Biotech as the target price of 215 € is below the current price of 222.1 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Krystal Biotech stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Krystal Biotech in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | -1.560% | -1.157% | -8.601% | 29.845% | 2.445% | 219.568% | - |
| Heron Therapeutics Inc. | -3.960% | -12.346% | -25.100% | -65.830% | -32.765% | -65.516% | -94.563% |
| Evolus Inc | 0.950% | -4.405% | 17.297% | -62.586% | -20.367% | -45.750% | -60.311% |
| Sangamo Therapeutics Inc. | -2.000% | -6.094% | 6.294% | -61.957% | -4.403% | -82.443% | -96.619% |
Comments
Krystal Biotech (KRYS) had its price target raised by Guggenheim from $224.00 to $284.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $220.00 to $323.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for KRYS provided by MarketBeat